新股消息 | 维健医药递表港交所

Core Viewpoint - Vigen International Holdings Limited (Vigen Pharma) has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as its sole sponsor, indicating its intention to go public and expand its operations in the pharmaceutical sector focused on kidney and blood diseases [1] Company Overview - Vigen Pharma is a leading comprehensive pharmaceutical company in China, specializing in the treatment of kidney and blood diseases, with capabilities in drug development, production, and commercialization [1] - The company aims to address significant unmet clinical needs in the treatment of kidney and blood diseases and other major diseases by providing innovative and valuable therapeutic solutions [1] Product Portfolio - Vigen Pharma has developed a diverse and differentiated product portfolio that covers a wide range of kidney and blood diseases, as well as extending into other major disease areas such as respiratory and skin diseases [1] - According to Zhi Shi Consulting, as of the last practicable date, Vigen Pharma's product portfolio includes six kidney drugs, making it the pharmaceutical company in China with the highest number of commercialized original drugs for kidney disease [1]